Letters To The Editor
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Nov 6, 2017; 8(4): 208-209
Published online Nov 6, 2017. doi: 10.4292/wjgpt.v8.i4.208
Fecal microbiota transplantation against irritable bowel syndrome? Rigorous randomized clinical trials are required
Amin Talebi Bezmin Abadi
Amin Talebi Bezmin Abadi, Department of Bacteriology, Faculty of Medical Science, Tarbiat Modares University, Tehran 14115, Iran
Author contributions: Abadi ATB designed the paper and approved the final manuscript.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Amin Talebi Bezmin Abadi, PhD, Assistant Professor, Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 111, Tehran 14115, Iran. amin.talebi@modares.ac.ir
Telephone: +98-21-82884883 Fax: +98-21-82884883
Received: June 18, 2017
Peer-review started: June 21, 2017
First decision: July 26, 2017
Revised: July 26, 2017
Accepted: September 5, 2017
Article in press: September 6, 2017
Published online: November 6, 2017
Processing time: 135 Days and 11 Hours
Core Tip

Core tip: Apart from the interesting report by Halkjær et al, there is a long list of tasks concerning the application of fecal microbiota transplantation for the treatment of irritable bowel syndrome. Route of delivery and optimum dosage are the major concerns to consider before using in clinical practice.